{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Melanoma+and+Other+Solid+Tumors&page=2",
    "query": {
      "condition": "Metastatic Melanoma and Other Solid Tumors",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Melanoma+and+Other+Solid+Tumors&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T00:28:46.509Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05907304",
      "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Naporafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erasca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 86,
      "start_date": "2023-08-17",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 14,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Sarasota, Florida + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05907304"
    },
    {
      "nct_id": "NCT05551117",
      "title": "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostatic Cancer",
        "Androgen-Independent Prostatic Cancer",
        "Androgen-Insensitive Prostatic Cancer",
        "Androgen-Resistant Prostatic Cancer",
        "Hormone Refractory Prostatic Cancer",
        "Anal Cancer",
        "Anal Neoplasm",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Head and Neck Squamous Cell Carcinoma",
        "Laryngeal Squamous Cell Carcinoma",
        "Oral Squamous Cell Carcinoma",
        "Malignant Melanoma",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Non-small Cell Carcinoma",
        "Small-cell Lung Cancer",
        "Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "vobramitamab duocarmazine 2.0 mg (Arm A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vobramitamab duocarmazine 2.7 mg (Arm B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vobramitamab duocarmazine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2023-06-13",
      "completion_date": "2025-01-23",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 14,
      "location_summary": "Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05551117"
    },
    {
      "nct_id": "NCT02166255",
      "title": "APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Recurrent Pancreatic Cancer",
        "Recurrent Renal Cell Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Renal Cell Cancer",
        "Stage IIIA Melanoma",
        "Stage IIIB Melanoma",
        "Stage IIIC Melanoma",
        "Stage IV Melanoma",
        "Stage IV Pancreatic Cancer",
        "Stage IV Renal Cell Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "siRNA-transfected peripheral blood mononuclear cells APN401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2014-12",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2018-07-03",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02166255"
    },
    {
      "nct_id": "NCT00003750",
      "title": "Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Neuroblastoma",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "hu14.18-IL2 fusion protein",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 28,
      "start_date": "2001-10",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2014-08-08",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 54,
      "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 44 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003750"
    },
    {
      "nct_id": "NCT03329950",
      "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Ovarian Cancer",
        "Cholangiocarcinoma",
        "Bladder Urothelial Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Hepatic Cancer",
        "Head and Neck Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer",
        "Other Solid Tumors",
        "Diffuse Large B-cell Lymphoma (DLBCL)",
        "Mantle Cell Lymphoma",
        "Indolent B-cell Lymphomas",
        "Non-Hodgkin Lymphoma",
        "Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Waldenstrom's Disease",
        "Marginal Zone Lymphoma",
        "Mucosa Associated Lymphoid Tissue",
        "Small Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CDX-1140",
          "type": "DRUG"
        },
        {
          "name": "CDX-301",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2017-12-01",
      "completion_date": "2022-09-13",
      "has_results": false,
      "last_update_posted_date": "2024-03-28",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03329950"
    },
    {
      "nct_id": "NCT02020707",
      "title": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Adenocarcinoma",
        "Cervical Adenosarcoma",
        "Cervical Adenosquamous Carcinoma",
        "Cervical Carcinosarcoma",
        "Cervical Squamous Cell Carcinoma",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Endometrial Adenosquamous Carcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Endometrioid Adenocarcinoma",
        "Endometrial Mixed Cell Adenocarcinoma",
        "Endometrial Mucinous Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Carcinosarcoma",
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Fallopian Tube Serous Adenocarcinoma",
        "Fallopian Tube Squamous Cell Carcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fallopian Tube Undifferentiated Carcinoma",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Ovarian Clear Cell Tumor",
        "Malignant Ovarian Endometrioid Tumor",
        "Malignant Ovarian Epithelial Tumor",
        "Malignant Ovarian Mucinous Tumor",
        "Malignant Peritoneal Neoplasm",
        "Malignant Solid Neoplasm",
        "Ovarian Carcinosarcoma",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian High Grade Serous Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Ovarian Undifferentiated Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Sensitive Ovarian Carcinoma",
        "Primary Peritoneal Carcinosarcoma",
        "Primary Peritoneal Clear Cell Adenocarcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Primary Peritoneal Transitional Cell Carcinoma",
        "Primary Peritoneal Undifferentiated Carcinoma",
        "Unresectable Melanoma",
        "Uterine Corpus Carcinosarcoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-02-24",
      "completion_date": "2024-07-18",
      "has_results": false,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02020707"
    },
    {
      "nct_id": "NCT03947385",
      "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Uveal Melanoma",
        "Cutaneous Melanoma",
        "Colorectal Cancer",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "IDE196",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IDEAYA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 336,
      "start_date": "2019-06-28",
      "completion_date": "2027-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03947385"
    },
    {
      "nct_id": "NCT00004016",
      "title": "Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "recombinant interferon gamma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-06",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004016"
    },
    {
      "nct_id": "NCT05081609",
      "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Locally Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Platinum-resistant Ovarian Cancer",
        "Post Anti-PD-1 Melanoma",
        "2L+ Cervical Cancer",
        "Neoadjuvant Melanoma",
        "Neoadjuvant Non-Small Cell Lung Cancer",
        "Post Anti-PD-(L)1 Non-Small Cell Lung Cancer",
        "Post Anti-PD-(L)1 Small Cell Lung Cancer",
        "Third Line or Later (3L+) HER2+ Breast Cancer",
        "Second or Third Line (2L/3L) Cervical Cancer",
        "Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)"
      ],
      "interventions": [
        {
          "name": "TransCon IL-2 β/γ",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy drug",
          "type": "DRUG"
        },
        {
          "name": "TransCon TLR7/8 Agonist",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine (T-DM1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ascendis Pharma Oncology Division A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2022-01-11",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05081609"
    },
    {
      "nct_id": "NCT05538130",
      "title": "A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Glioma",
        "Thyroid Cancer",
        "Non-Small Cell Lung Cancer",
        "Malignant Neoplasms",
        "Brain Neoplasms",
        "Advanced or Metastatic Solid Tumors",
        "HGG",
        "LGG",
        "Low Grade Glioma",
        "High Grade Glioma",
        "Differentiated Thyroid Cancer",
        "NSCLC (Non-small Cell Lung Cancer)"
      ],
      "interventions": [
        {
          "name": "PF-07799544",
          "type": "DRUG"
        },
        {
          "name": "PF-07799933",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2022-11-30",
      "completion_date": "2029-06-18",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-07-24T00:28:46.509Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05538130"
    }
  ]
}